cyc 202 has been researched along with rubitecan in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (rubitecan) | Trials (rubitecan) | Recent Studies (post-2010) (rubitecan) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 149 | 34 | 22 |
| Protein | Taxonomy | cyc 202 (IC50) | rubitecan (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 5.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Doniger, J; Mayner, R; Sadaie, MR | 1 |
1 review(s) available for cyc 202 and rubitecan
| Article | Year |
|---|---|
A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics.
Topics: Anti-HIV Agents; Antimetabolites; Antineoplastic Agents; Apoptosis; Camptothecin; Cyclin-Dependent Kinases; Flavonoids; HIV; HIV Infections; Humans; Piperidines; Purines; Receptors, Estrogen; Roscovitine; Topoisomerase I Inhibitors; Virus Replication | 2004 |
1 other study(ies) available for cyc 202 and rubitecan
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |